CORRIGENDUM to ‘Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN’

John H Krege, Paul B Rizzoli, Emily Liffick, et al. Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN. Cephalalgia 2019; 39(8): 957–966. DOI: 10.1177/0333102419855080.

On page 960, top of the right-hand column, the sentence incorrectly stated ‘The only SAE with incidence >1% in any group was dizziness in the lasmiditan 200 mg group.’

This sentence should correctly state ‘The only severe TEAE with incidence >1% in any group was dizziness in the lasmiditan 200 mg group’.